Guideline Recommendations The 2023 American Association of Clinical Endocrinology (AACE) Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity recommend GLP-1 receptor agonists, including semaglutide 2.4 mg, as first-line pharmacotherapy for adults with BMI 30 or BMI 27 with a weight-related complication
PlexusDx starting semaglutide at $189/month allows patients to begin treatment immediately while tracking real-world progress toward personal goals
Ongoing clinical care takes place through messaging
Most patients begin noticing reduced hunger within the first two weeks, though the pace and magnitude of weight loss vary based on individual metabolism, starting dose, and genetic factors that influence how your body processes this medication
Performance metrics If you are resistance training, track your lifts
In just 3 weeks my dark spots have faded and my skin literally glows every morning